- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02465359
Subcutaneous Immunoglobulin for CIDP (SCIG)
September 14, 2021 updated by: University of South Florida
A Study of Subcutaneous Immunoglobulin as Chronic Treatment for Patients With Chronic Inflammatory Demyelinating Polyneuropathy
The investigators are using self administered subcutaneous IG in patients with CIDP who require IVIG.
Safety, efficacy, and patient satisfaction will be examined.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune neurological disorder that causes limb weakness and numbness.
Many patients require immunosuppressants and plasma exchange (PLEX) to control their symptoms.
Intravenous immunoglobulin (IVIG)is also an effective treatment (Hughes et al, 2006 & 2008; Hughes, 2009; Cocito et al, 2010), and the American Academy of Neurology (AAN) guideline recommended that it should be offered in the long-term treatment of CIDP (Patwa et al, 2012).
While effective, IVIG causes systemic side effects in about 5% of patients.
These side effects include rash, pruritus, myalgia, fever, chills, headache, low back pain, nausea, vomiting, changes in blood pressure or heart rate, renal failure, and aseptic meningitis (Berger, 2008).
For many patients who are chronically treated with IVIG, venous access may be a problem over time.
An alternative is the subcutaneous (SC) route, which has been in use since 1980 for primary immune deficiency disorders and is the treatment of choice for this condition in Scandinavia and England (Radinsky et al, 2003).
As compared to IV route, SC route maintains higher trough levels of immunoglobulins, increases patient independence, reduces systemic side-effects, and is better tolerated in those who are pregnant or sensitized to IgA (Radinsky et al, 2003).
In a review of side effects associated with 33,168 SCIG infusions, no severe or anaphylactoid reactions occurred (Gardulf et al, 1995).
Patients can self-administer medication, and hence, overall cost may be reduced.
A retrospective study of 28 children with primary immunodeficiency in Canada showed that the mean difference in costs between IVIG and SCIG during the study period (1 year on IVIG and 1 year on SCIG) was $4,346 in favor of SCIG (Ducruet et al, 2011).
A US$10,100 reduction in cost per year per patient associated with SCIG use was also reported by Gardulf et al (1995) in Sweden.
Disadvantages of SCIG include more frequent infusions and local reactions at sites of infusion (transient swelling, soreness, redness, induration, local heat, and itching) in about 1% of patients.
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33612
- USF Dept of Neurology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
To qualify, a patient must have CIDP and persistence of significant symptoms (having 2 or more of the following):
- Weakness in any limb,
- Motor fatigue significant to interfere with ADL or work,
- Paresthesia of sufficient severity to require a medication,
- Sensory impairment,
- Walking impairment,
AND requires IVIG to control symptoms.
Exclusion Criteria:
- Thrombocytopenia or other bleeding disorders,
- Anticoagulation therapy,
- Severe or anaphylactoid reactions to IVIG,
- Cancer,
- Pregnancy,
- Breast-feeding,
- Renal insufficiency or failure,
- Congestive heart failure,
- Psychiatric illness.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Immune globulin subcutaneous (Human)
lmmune Globulin Subcutaneous(Human) 20% Liquid (Hizentra) will be given weekly
|
Patients who have CIDP and are on IVIG will be allowed in the study to try subcutaneous immune Globulin (SCIG) as part of an open label study.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relapse of CIDP Symptoms
Time Frame: 6 months
|
This is defined as a 20% decrease in force (as detected on Hand-Held Dynamometry (HHD)) in greater that 50% of the muscles tested compared to baseline values
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Short Form 36
Time Frame: Monthly for six months
|
This questionnaire evaluates the patient's health status
|
Monthly for six months
|
Rasch-built Overall Disability Scale
Time Frame: Monthly for 6 months
|
The Rasch-built Overall Disability Scale (R-ODS) is an instrument answered by the patient to assess overall disability
|
Monthly for 6 months
|
CIP-PRO20
Time Frame: Monthly for 6 months
|
The CIP-PRO20 is used to evaluate quality of life in patients with polyneuropathy
|
Monthly for 6 months
|
Treatment Satisfaction Questionnaire for Medication
Time Frame: 2-6 weeks prior to Day 1 of treatment and then monthly for 6 months
|
The TSQM is the Treatment Satisfaction Questionnaire for Medication will be used to assess the patient's satisfaction with IVIg treatment compared to the use of SCIg treatment
|
2-6 weeks prior to Day 1 of treatment and then monthly for 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Tuan Vu, MD, University of South Florida
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2014
Primary Completion (Actual)
March 1, 2018
Study Completion (Actual)
May 1, 2021
Study Registration Dates
First Submitted
December 12, 2014
First Submitted That Met QC Criteria
June 4, 2015
First Posted (Estimate)
June 8, 2015
Study Record Updates
Last Update Posted (Actual)
September 16, 2021
Last Update Submitted That Met QC Criteria
September 14, 2021
Last Verified
September 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Immune System Diseases
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Neuromuscular Diseases
- Peripheral Nervous System Diseases
- Polyradiculoneuropathy
- Polyneuropathies
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Physiological Effects of Drugs
- Immunologic Factors
- Antibodies
- Immunoglobulins
- Immunoglobulins, Intravenous
- gamma-Globulins
- Rho(D) Immune Globulin
Other Study ID Numbers
- Pro00016957
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Inflammatory Demyelinating Polyneuropathy
-
University of AarhusOdense University Hospital; Aarhus University Hospital; Rigshospitalet, Denmark; Aalborg University HospitalRecruitingCIDP - Chronic Inflammatory Demyelinating PolyneuropathyDenmark
-
Vera BrilUnknownChronic Inflammatory Demyelinating Polyneuropathy (CIDP)Canada
-
University Hospital, BordeauxRecruitingChronic Inflammatory Demyelinating Polyneuropathy (CIDP)France
-
CSL BehringCompletedPolyradiculoneuropathy, Chronic Inflammatory Demyelinating | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)United States, Japan, Australia, Canada, Czechia, France, Germany, Italy, Netherlands, Spain, United Kingdom
-
SanofiRecruitingChronic Inflammatory Demyelinating Polyradiculoneuropathy | Polyneuropathy, Inflammatory Demyelinating, ChronicUnited States
-
OctapharmaRecruitingPediatric Chronic Inflammatory Demyelinating PolyneuropathyUnited States
-
Centre Hospitalier Universitaire de Saint EtienneLaboratoire français de Fractionnement et de BiotechnologiesCompletedDemyelinating PolyneuropathyFrance
-
UCB Biopharma SRLNo longer availableChronic Inflammatory Demyelinating Polyneuropathy (CIDP)
-
CSL BehringRecruitingPediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)United States
-
argenxCompletedChronic Inflammatory Demyelinating Polyneuropathy (CIDP)United States, Austria, Belgium, Bulgaria, China, Czechia, Denmark, France, Georgia, Germany, Hungary, Israel, Italy, Japan, Latvia, Netherlands, Poland, Romania, Russian Federation, Serbia, Spain, Taiwan, Turkey, Ukraine, United Kingdom
Clinical Trials on Immune Globulin Subcutaneous (Human)
-
Rochester General HospitalTakedaRecruitingCOPD Exacerbation AcuteUnited States
-
Baxalta now part of ShireCompletedPrimary Immunodeficiency Diseases (PID)Germany, Austria, Hungary, Sweden, United Kingdom
-
Baxalta now part of ShireCompletedPrimary Immunodeficiency Diseases (PID)Japan
-
CSL BehringCompletedPrimary Immune Deficiency DisorderJapan
-
Baxalta now part of ShireCompleted
-
CSL BehringCompleted
-
TakedaTakeda Development Center Americas, Inc.RecruitingPrimary Immunodeficiency Diseases (PID)United States
-
Mazen Dimachkie, MDCSL BehringCompletedMyasthenia GravisUnited States, Canada
-
TakedaTakeda Development Center Americas, Inc.; Baxalta Innovations GmbH, now part...Completed
-
TakedaTakeda Development Center Americas, Inc.Not yet recruitingPrimary Immunodeficiency Diseases (PID)